Search results for "NEOPLASIA"

showing 10 items of 177 documents

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

2021

The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and brid…

BendamustineOncologymedicine.medical_specialtyCancer ResearchImmunoconjugatesMedizinSalvage therapyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProgression-free survivalRetrospective StudiesSalvage TherapyLymphoid Neoplasiabusiness.industryAntibodies MonoclonalHematologyChemotherapy regimenPolatuzumab vedotinTransplantationRegimenbacteriaRituximabbusinessmedicine.drug
researchProduct

The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state

2012

AbstractMiR-125b-1 maps at 11q24, a chromosomal region close to the epicenter of 11q23 deletions in chronic lymphocytic leukemias (CLLs). Our results establish that both aggressive and indolent CLL patients show reduced expression of miR-125b. Overexpression of miR-125b in CLL-derived cell lines resulted in the repression of many transcripts encoding enzymes implicated in cell metabolism. Metabolomics analyses showed that miR-125b overexpression modulated glucose, glutathione, lipid, and glycerolipid metabolism. Changes on the same metabolic pathways also were observed in CLLs. We furthermore analyzed the expression of some of miR-125b–target transcripts that are potentially involved in the…

Blotting WesternImmunologyBiologyReal-Time Polymerase Chain ReactionBiochemistryNODownregulation and upregulationmicroRNABiomarkers TumorHumansMetabolomicsRNA MessengerPsychological repressionCells CulturedCell ProliferationOligonucleotide Array Sequence AnalysisRegulation of gene expressionB-LymphocytesLymphoid NeoplasiaReverse Transcriptase Polymerase Chain ReactionCell growthGene Expression ProfilingCell BiologyHematologyLeukemia Lymphocytic Chronic B-CellMolecular biologyGene Expression Regulation NeoplasticGene expression profilingMicroRNAsMetabolic pathwayCell Transformation NeoplasticChromosomal regionCancer researchBlood
researchProduct

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological c…

2022

Abstract Background The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself. This work aims to study the situation of biomarker testing in Spain. Patients and methods The Thoracic Tumours Registry (TTR) is an observational, prospective, registry-based study that included patients diagnosed with lung cancer and other thoracic tumours, from September 2016 to 2020. This TTR study was sponsored by the Spanish Lung Cancer Group (GECP) Foundation, an independent, scientific, multidisciplinary oncology society that coordinates…

Cancer Research:Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms [DISEASES]Lung NeoplasmsTesting:Biological Factors::Biomarkers [CHEMICALS AND DRUGS]:factores biológicos::biomarcadores [COMPUESTOS QUÍMICOS Y DROGAS]Targeted therapiesPulmons - Càncer:neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares [ENFERMEDADES]Carcinoma Non-Small-Cell LungProto-Oncogene ProteinsGeneticsBiomarkers TumorHumansProspective StudiesCàncerDemographyReceptor Protein-Tyrosine KinasesProtein-Tyrosine KinasesErbB ReceptorsOncologySpainPulmonsMarcadors bioquímicsBiomarkersMetastatic lung cancer
researchProduct

Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations.

2013

Human papillomavirus (HPV) 58 accounts for a notable proportion of cervical cancers in East Asia and parts of Latin America, but it is uncommon elsewhere. The reason for such ethnogeographical predilection is unknown. In our study, nucleotide sequences of E6 and E7 genes of 401 HPV58 isolates collected from 15 countries/cities across four continents were examined. Phylogenetic relationship, geographical distribution and risk association of nucleotide sequence variations were analyzed. We found that the E6 genes of HPV58 variants were more conserved than E7. Thus, E6 is a more appropriate target for type-specific detection, whereas E7 is more appropriate for strain differentiation. The frequ…

Cancer ResearchSettore MED/07 - Microbiologia E Microbiologia Clinicacervical cancerSettore MED/06 - Oncologia MedicaPapillomavirus E7 ProteinsUterine Cervical NeoplasmsCervix UteriphylogenyPolymerase Chain ReactionViralPapillomaviridaePapillomaviridaePhylogenyCancerOncogene ProteinsCervical cancerGeneticsTumorGeographybiologyNucleic acid sequenceDNA NeoplasmPrognosisInfectious DiseasesOncologyHIV/AIDSFemaleHPVhuman papillomavirus type 58 E6 and E7 sequence variationsOncology and CarcinogenesisCervical intraepithelial neoplasiaRisk AssessmentArticleVaccine Relatedoncogenic riskClinical ResearchPhylogeneticsGenetic variationGeneticsBiomarkers TumormedicineHumansOncology & CarcinogenesisGenePreventionPapillomavirus InfectionsGenetic VariationInternational AgenciesDNAOncogene Proteins ViralOdds ratioUterine Cervical Dysplasiamedicine.diseasebiology.organism_classificationVirologyvariantNeoplasmSexually Transmitted InfectionsCapsid ProteinsBiomarkersFollow-Up Studies
researchProduct

Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controv…

2016

Contains fulltext : 171468pub.pdf (Publisher’s version ) (Open Access) Primary treatment of rectal cancer was the focus of the second St. Gallen European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Conference. In the context of the conference, a multidisciplinary international expert panel discussed and voted on controversial issues which could not be easily answered using published evidence. Main topics included optimal pretherapeutic imaging, indication and type of neoadjuvant treatment, and the treatment strategies in advanced tumours. Here we report the key recommendations and summarise the related evidence. The treatment strategy for localised rect…

Cancer ResearchStagingColorectal cancermedicine.medical_treatmentNeoplasias Gastrointestinais030230 surgerySYNCHRONOUS LIVER METASTASESImagingCOLORECTAL-CANCER0302 clinical medicineADJUVANT CHEMOTHERAPYTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]SHORT-COURSE RADIOTHERAPYRectal cancerNeoadjuvant therapyGastrointestinal NeoplasmsRectal Neoplasms/drug therapyCombination chemotherapyChemoradiotherapyCombined Modality TherapyTotal mesorectal excisionNeoadjuvant TherapyEuropeNeoplasias do Recto/quimioterapiaOncology030220 oncology & carcinogenesisMEDIAN FOLLOW-UPLife Sciences & BiomedicineDiagnostic Imagingmedicine.medical_specialtyAntineoplastic AgentsLOCAL RECURRENCERisk AssessmentCOURSE PREOPERATIVE RADIOTHERAPY03 medical and health sciencesmedicineHumansGastrointestinal cancerOncology & CarcinogenesisRadiochemotherapyNeoplasm StagingScience & TechnologyRadiotherapyRectal Neoplasmsbusiness.industryGeneral surgeryTOTAL MESORECTAL EXCISIONCancerRANDOMIZED PHASE-IIImedicine.diseaseSurgeryRadiation therapySurgerybusiness1112 Oncology And CarcinogenesisChemoradiotherapyPOSTOPERATIVE CHEMORADIOTHERAPY
researchProduct

The Porto European Cancer Research Summit 2021.

2021

Key stakeholders from the cancer research continuum met in May 2021 at the European Cancer Research Summit in Porto to discuss priorities and specific action points required for the successful implementation of the European Cancer Mission and Europe's Beating Cancer Plan (EBCP). Speakers presented a unified view about the need to establish high‐quality, networked infrastructures to decrease cancer incidence, increase the cure rate, improve patient's survival and quality of life, and deal with research and care inequalities across the European Union (EU). These infrastructures, featuring Comprehensive Cancer Centres (CCCs) as key components, will integrate care, prevention and research acros…

Cancer Researchmedicine.medical_specialty:Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores]infrastructures for translational cancer researchDeclarationTranslational researchContext (language use)comprehensive cancer centresMeeting Reportclinical/prevention trials:profesiones sanitarias::medicina::medicina clínica::medicina de precisión [DISCIPLINAS Y OCUPACIONES]Translational Research Biomedicaloutcomes research:neoplasias [ENFERMEDADES]:Other subheadings::Other subheadings::/prevention & control [Other subheadings]cancer research/care/prevention continuumNeoplasmsPolitical scienceGeneticsmedicineHumansmedia_common.cataloged_instance:Health Occupations::Medicine::Clinical Medicine::Precision Medicine [DISCIPLINES AND OCCUPATIONS]Medicina personalitzadaPrecision MedicineEuropean unionRC254-282media_commongeographySummitgeography.geographical_feature_categoryHealth economics:Natural Science Disciplines::Science::Research::Biomedical Research [DISCIPLINES AND OCCUPATIONS]Neoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineCancer MissionEuropescience policy:Neoplasms [DISEASES]Medicina - InvestigacióOncologyQuality of LifeCancer researchMolecular MedicineScience policyCàncer - PrevencióOutcomes research:disciplinas de las ciencias naturales::ciencia::investigación::investigación biomédica [DISCIPLINAS Y OCUPACIONES]
researchProduct

The optimal age for performing surgery on patients with MEN 2B syndrome

2011

Multiple endocrine neoplasia (MEN) syndromes are characterized by the association of various endocrine neoplasias. Prophylactic thyroidectomy is the treatment of choice for patients with RET gene mutations. The age at which patients undergo prophylactic thyroidectomy may vary depending on the position of the RET gene codon. In cases of MEN 2B, when the mutation is carried in codons 883, 918 or 922, prophylactic thyroidectomy is performed prior to 6 months of age, due to the increased aggressiveness of these heterozygosities, which are capable of determining the onset of medullary cancer during the first months of life. We present two heterozygous twin patients with MEN 2B syndrome who were …

Cancer Researchmedicine.medical_specialtyMedullary cavitybusiness.industryCancermedicine.diseaseMolecular medicineSurgeryThyroid carcinomamedicine.anatomical_structureOncologymedicineEndocrine systemmedicine.symptomMultiple endocrine neoplasiabusinessLymph nodeWeight gainResearch Article
researchProduct

Experimental evolution of an oncolytic vesicular stomatitis virus with increased selectivity for p53-deficient cells

2014

Experimental evolution has been used for various biotechnological applications including protein and microbial cell engineering, but less commonly in the field of oncolytic virotherapy. Here, we sought to adapt a rapidly evolving RNA virus to cells deficient for the tumor suppressor gene p53, a hallmark of cancer cells. To achieve this goal, we established four independent evolution lines of the vesicular stomatitis virus (VSV) in p53-knockout mouse embryonic fibroblasts (p53-/- MEFs) under conditions favoring the action of natural selection. We found that some evolved viruses showed increased fitness and cytotoxicity in p53-/- cells but not in isogenic p53+/+ cells, indicating gene-specifi…

Cancer TreatmentVirus OncolíticosProtein EngineeringMiceMedicine and Health SciencesMacromolecular EngineeringMice KnockoutOncolytic VirotherapyMultidisciplinaryQProteína p53 Supresora de TumorRNeoplasias de la Mama3. Good healthOncolytic VirusesOncologyVesicular stomatitis virusColonic NeoplasmsMedicineFemaleVesicular StomatitisResearch ArticleBiotechnologyDirected EvolutionEvolutionary ProcessesTumor suppressor geneScienceBioengineeringBreast NeoplasmsBiologyMicrobiologyViral EvolutionVirusVesicular StomatitisVirologyCell Line TumorGeneticsAnimalsHumansEvolutionary BiologyNeoplasias del ColonBiology and Life SciencesRNA virusVesiculovirusbiology.organism_classificationVirologyOrganismal EvolutionOncolytic virusAnimal Models of InfectionArtificial SelectionSynthetic BioengineeringViruses and CancerCell cultureMicrobial EvolutionCancer cellCancer researchDirected Molecular EvolutionTumor Suppressor Protein p53
researchProduct

The Short-Access Mother–Baby-(SAMBA) Cholangioscopy System

2014

Conventional mother–baby cholangioscopy systems have significant limitations including poor image resolution, limited maneuverability and fragile cholangioscopes. We propose the novel short-access mother–baby-(SAMBA) cholangioscopy system that involves a very short and flexible cholangioscope that is introduced in a dedicated mother duodenoscope with an extra distal side port. Clinical feasibility of this device is demonstrated in three complex cases with cholangiopathies. The strengths of SAMBA cholangioscopy are improved imaging quality and excellent maneuverability of the baby that allows access of small intrahepatic ducts. Evaluation of suspected intrahepatic biliary disease is an excel…

Cholangiopathymedicine.medical_specialtylcsh:Medical technologyNeoplasiabusiness.industryGastroenterologyVideoSecondary sclerosing cholangitisCholangiocellular carcinomamedicine.diseaseBiliary diseasePort (medical)lcsh:R855-855.5Cholangiocellular carcinomaLaser lithoripsyImaging qualitymedicineSecondary sclerosing cholangitisCholangioscopyMother–baby cholangioscopyRadiology Nuclear Medicine and imagingRadiologybusinessVideo Journal and Encyclopedia of GI Endoscopy
researchProduct

Prospective Comparison of Loop Excision under Colposcopic Guidance versus Vitom Guidance.

2012

Background: Aim of the study was to compare the quality of loop excision using a colposcope with results using the VITOM system. Results compared included cervical volume removed, intra- and postoperative complications, and positive resection margins. Methods: A total of 200 patients with histologically confirmed high-grade cervical premalignant lesions, persistent atypical cytological results and/or suspicious colposcopic findings, and cytological and histological discrepancies were included in the study. In transformation zone type 1 (T1) only a superficial cone biopsy was done, in zones type 2 and 3 (T2 and T3) a superficial outside cone biopsy or a deeper inside cone biopsy were done re…

ColposcopyCervical cancermedicine.medical_specialtymedicine.diagnostic_testbusiness.industrycervical cancerObstetrics and GynecologyEndocervical curettagemedicine.diseasecervical intraepithelial neoplasia (CIN)Settore MED/40 - Ginecologia E OstetriciaArticleResectionSurgerycervical cancer; cervical intraepithelial neoplasia (CIN); cervical precancerous condition; Obstetrics and Gynecology; Maternity and MidwiferyColposcopeCone biopsyMaternity and MidwiferyMedicinecervical precancerous conditionLoop excisionTransformation zonebusinessGeburtshilfe und Frauenheilkunde
researchProduct